Basit öğe kaydını göster

dc.contributor.authorAK, Naziye
dc.contributor.authorAYDINER, Adnan
dc.contributor.authorPaksoy, Nail
dc.contributor.authorVATANSEVER, Sezai
dc.contributor.authorSaip, Pınar
dc.contributor.authorDOĞAN, İzzet
dc.date.accessioned2023-05-29T13:42:25Z
dc.date.available2023-05-29T13:42:25Z
dc.date.issued2023
dc.identifier.citationDOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A., "Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine", European Journal of Breast Health, cilt.19, sa.2, ss.128-133, 2023
dc.identifier.issn2587-0831
dc.identifier.othervv_1032021
dc.identifier.otherav_3a884164-9b06-4257-b2c4-6232e03be4c3
dc.identifier.urihttp://hdl.handle.net/20.500.12627/189093
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/3a884164-9b06-4257-b2c4-6232e03be4c3/file
dc.identifier.urihttps://doi.org/10.4274/ejbh.galenos.2023.2022-12-4
dc.description.abstractObjective: The aim was to assess the prognostic variables in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients receiving lapatinib plus capecitabine. Materials and Methods: Retrospective data on HER2-positive metastatic breast cancer patients who received lapatinib and capecitabine were analyzed. Survival outcome was obtained with Cox regression analysis and the Kaplan–Meier method. Results: The study included 102 patients. Forty-four (43.1%) patients had de novo metastatic disease. The most frequent metastatic sites were, in order, bone (61.8%), brain (57.8%), liver (35.3%), and lung (34.3%). All of the patients had previously received chemotherapy based on trastuzumab. With combined lapatinib and capecitabine, complete response was observed in 7.8%, partial response in 30.4%, and stable disease in 24.5%. Progression-free survival was 8 (95% confidence interval, 5.1–10.8) months. In multivariable analysis, endocrine therapy (p = 0.02), de novo metastatic disease (p = 0.02), and age (p = 0.02) were prognostic factors for progression-free survival. However, the number of chemotherapy cycles with trastuzumab, palliative radiotherapy, history of breast surgery, and the number of metastatic sites were not significant in this respect. Conclusion: These results have demonstrated the effectiveness of lapatinib plus capecitabine in metastatic HER2-positive breast cancer patients. Furthermore, unfavorable prognostic factors for progression-free survival were shown to be hormone-negative tumor, de novo metastatic disease, and young age.
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectNükleer Tıp
dc.subjectCerrahi Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectCerrahi
dc.subjectRadyoloji, Nükleer Tıp ve Görüntüleme
dc.subjectDahiliye
dc.subjectRADYOLOJİ, NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectONKOLOJİ
dc.subjectCERRAHİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTIP, GENEL & DAHİLİ
dc.titlePrognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine
dc.typeMakale
dc.relation.journalEuropean Journal of Breast Health
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume19
dc.identifier.issue2
dc.identifier.startpage128
dc.identifier.endpage133
dc.contributor.firstauthorID4265555


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster